Your report is ready
Click below to download Guiding Principles in Biotech Valuation.
Click here to download the Biotech Valuations Report.
WHAT'S INSIDE:
-
How rNPV differs from standard DCF — and why it matters for early-stage assets
-
Step-by-step breakdown of net cash flow modelling for therapeutic candidates
-
How risk weightings are applied at each development stage (preclinical through regulatory approval)
-
How discount rates are constructed for biotech and drug development companies
-
How market comparables are used as a secondary cross-check — and where they fall short
Why Choose Sherwood for Valuations
✓ AFSL Licence No. 563351 — Sherwood Australia is licensed to provide equity valuations
✓ 250+ valuations delivered across biotech, medtech, AI, and deep tech
✓ Used by founders, investors, and boards across Australia and internationally
Our track record
50+
companies advised
$500M+
transaction value
$5-$350M
deal size range
in 12
countries on 4 continents
Need a Valuation for Your Specific Asset?
Contact Anthony Vago today at anthony@sherwoodaustralia.com.au or +61 406 155 571 for a confidential discussion, or leave your details here and our valuations experts will get in touch with you within 24 hours.
A Proud Member of Sherwood Global Partners
As part of Sherwood Global Partners, we tap into a powerful international network of corporate finance experts, strategic partners, and investors — bringing global opportunity to every transaction.